Interventional trial in Puerto Rico

Everything is set to start testing LVOne in Puerto Rico. In collaboration with Hospital Menonita Caguas, we will be trialling our stroke blood test.

Stroke remains a critical public health issue in Puerto Rico, representing the leading cause of long-term disability on the island. The high prevalence of risk factors, combined with significant mortality rates and healthcare disparities, underscores the urgent need for improved diagnostic and treatment strategies. 

One of the most time-sensitive and dangerous forms of stroke is Large Vessel Occlusion (LVO). Rapid identification of LVO is essential, as timely intervention, such as mechanical thrombectomy – can drastically reduce long-term disability and improve patient outcomes. 

Upfront Diagnostics, in collaboration with Hospital Menonita Caguas, Inc., is launching a pioneering clinical study to evaluate its novel stroke blood test, LVOne. The study, titled COPILOT, will assess the clinical effectiveness of LVOne in patients presenting with suspected stroke. The trial, which has received IRB approval, is ready to commence and will run for a minimum of 24 months. It represents a major milestone for stroke care in Puerto Rico and potentially around the world. 

Story by Upfront Diagnostics